GlassScriptPhysician profile
Michael Lee Nunnery
NPI 1194736512
$1,622.69
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $192.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $235.38 | 2019-2020 | |
| Amgen INC. | $214.67 | 2019-2020 | |
| Lilly USA, LLC | $125.06 | 2019 | |
| Merck Sharp & Dohme LLC | $112.36 | 2019 | |
| Amarin Pharma, INC. | $94.16 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $90.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $90.08 | 2019-2020 | |
| Astellas Pharma US INC | $78.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $42.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $41.89 | 2019-2020 | |
| Abbvie INC. | $41.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $40.65 | 2019-2020 | |
| Radius Health, INC. | $38.45 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.24 | 2019 | |
| Genentech USA, INC. | $33.50 | 2019 | |
| Adlon Therapeutics L.P. | $32.19 | 2019 | |
| Novo Nordisk INC | $25.93 | 2019 | |
| Ironwood Pharmaceuticals, INC | $25.03 | 2019 | |
| Upsher-Smith Laboratories LLC | $20.29 | 2020 | |
| Irhythm Technologies, INC. | $16.59 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.46 | 2019 | |
| Allergan, INC. | $11.40 | 2019 | |
| Boston Scientific Corporation | $11.33 | 2019 | |
| Abbott Laboratories | $11.17 | 2019 | |
| Pfizer INC. | $11.17 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nunnery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.